Raffaela Rametta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7224896/publications.pdf

Version: 2024-02-01

62 papers	5,247 citations	81743 39 h-index	118652 62 g-index
62 all docs	62 docs citations	62 times ranked	6114 citing authors

#	Article	IF	Citations
1	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
2	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
3	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
4	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	1.8	309
5	PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Human Molecular Genetics, 2014, 23, 4077-4085.	1.4	293
6	Patatin-Like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 2011, 53, 791-799.	3.6	227
7	Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Diabetes, 2008, 57, 1355-1362.	0.3	163
8	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
9	Dietary Iron Overload Induces Visceral Adipose Tissue Insulin Resistance. American Journal of Pathology, 2013, 182, 2254-2263.	1.9	128
10	DJ-1 Modulates Î±-Synuclein Aggregation State in a Cellular Model of Oxidative Stress: Relevance for Parkinson's Disease and Involvement of HSP70. PLoS ONE, 2008, 3, e1884.	1.1	116
11	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	1.8	106
12	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
13	Î±1-Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology, 2006, 44, 857-864.	3.6	88
14	A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World Journal of Gastroenterology, 2014, 20, 3002.	1.4	85
15	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. Scientific Reports, 2019, 9, 11585.	1.6	82
16	Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 568-575.	1.1	78
17	Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 683-690.	1.1	78
18	Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease. Diabetes, 2013, 62, 4052-4062.	0.3	78

#	Article	IF	Citations
19	PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity ,. Journal of Nutrition, 2015, 145, 1687-1691.	1.3	78
20	Protective effect of TATâ€delivered Î±â€synuclein: relevance of the Câ€terminal domain and involvement of HSP70. FASEB Journal, 2004, 18, 1713-1715.	0.2	77
21	Genetic and Epigenetic Modifiers of Alcoholic Liver Disease. International Journal of Molecular Sciences, 2018, 19, 3857.	1.8	75
22	Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker. Gut, 2020, 69, 1855-1866.	6.1	75
23	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
24	Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine, 2020, 52, 102658.	2.7	71
25	Iron-Dependent Regulation of MDM2 Influences p53 Activity and Hepatic Carcinogenesis. American Journal of Pathology, 2010, 176, 1006-1017.	1.9	68
26	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
27	Paradoxical Dissociation Between Hepatic Fat Content and De Novo Lipogenesis Due to PNPLA3 Sequence Variant. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E821-E825.	1.8	64
28	Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. Clinical Science, 2017, 131, 1301-1315.	1.8	64
29	The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls. BMC Gastroenterology, 2012, 12, 111.	0.8	62
30	Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2010, 53, 927-933.	1.8	60
31	LPIN1 rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
32	Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2010, 10, 102.	0.8	53
33	Patatin-like phospholipase domain containing-3gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. World Journal of Gastroenterology, 2012, 18, 2813.	1.4	50
34	High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload. PLoS ONE, 2015, 10, e0116855.	1.1	47
35	The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development â€“ a potential therapeutic target?. Expert Review of Gastroenterology and Hepatology, 2016, 10, 229-242.	1.4	44
36	The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e48804.	1.1	42

#	Article	IF	Citations
37	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
38	PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e75982.	1.1	42
39	The <scp>UCP</scp>2 â€866ÂG>A promoter region polymorphism is associated with nonalcoholic steatohepatitis.. Liver International, 2015, 35, 1574-1580.	1.9	41
40	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. Journal of Hepatology, 2021, 75, 506-513.	1.8	40
41	Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease. Hepatology Communications, 2018, 2, 666-675.	2.0	38
42	Hepcidin resistance in dysmetabolic iron overload. Liver International, 2016, 36, 1540-1548.	1.9	36
43	Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. Journal of Hepatology, 2012, 57, 1319-1325.	1.8	33
44	HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1331-1337.	2.2	27
45	PCSK9 rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	1.9	26
46	Dysmetabolic Hyperferritinemia and Dysmetabolic Iron Overload Syndrome (DIOS): Two Related Conditions or Different Entities?. Current Pharmaceutical Design, 2020, 26, 1025-1035.	0.9	26
47	A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. Journal of Viral Hepatitis, 2011, 18, 628-630.	1.0	24
48	Hepatic steatosis and <scp>PNPLA</scp>3 I148<scp>M</scp> variant are associated with serum <scp>F</scp>etuinâ€<scp>A</scp> independently of insulin resistance. European Journal of Clinical Investigation, 2014, 44, 627-633.	1.7	24
49	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrology, 2013, 14, 48.	0.8	20
50	HFE Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 101-107.	1.4	19
51	Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nature Communications, 2021, 12, 1822.	5.8	17
52	Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFEâ€related hemochromatosis. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1342-1348.	1.4	15
53	Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. Journal of Hepatology, 2013, 58, 399-401.	1.8	14
54	<i>HFE</i> Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study. American Journal of Nephrology, 2008, 28, 311-316.	1.4	13

#	Article	IF	Citations
55	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	12
56	GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. Annals of Hepatology, 2017, 16, 451-456.	0.6	10
57	A novel alpha1-antitrypsin null variant (PiQ0Milano). World Journal of Hepatology, 2013, 5, 458.	0.8	8
58	Impact of natural neuromedinâ€Β receptor variants on iron metabolism. American Journal of Hematology, 2020, 95, 167-177.	2.0	7
59	From Environment to Genome and Back: A Lesson from HFE Mutations. International Journal of Molecular Sciences, 2020, 21, 3505.	1.8	7
60	Increased circulating adiponectin in males with chronic HCV hepatitis. European Journal of Internal Medicine, 2015, 26, 635-639.	1.0	6
61	GNPAT p.D519G variant and iron metabolism during oral iron tolerance test. Hepatology, 2017, 65, 384-385.	3.6	5
62	Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. Annals of Hepatology, 2014, 13, 568-71.	0.6	1